Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer

References

• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol.167(2 Pt 2), 948–951 (2002).
   PubMed Web of Science ®Google Scholar
• Nesbit RM, Baum WC. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. J. Am. Med. Assoc.143(15), 1317–1320 (1950).
   PubMed Web of Science ®Google Scholar
• Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J. Urol.179(5 Suppl.), S53–S59 (2008).
   Google Scholar
• Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J. Urol.177(6), 1985–1991 (2007).
   Google Scholar
• Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J. Clin. Oncol.27(10), 1557–1563 (2009).
   PubMed Web of Science ®Google Scholar
• Maroni PD, Crawford ED. The benefits of early androgen blockade. Best Pract. Res. Clin. Endocrinol. Metab.22(2), 317–329 (2008).
   Google Scholar
• Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol.7(6), 472–479 (2006).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA299(3), 289–295 (2008).
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med.339(15), 1036–1042 (1998).
   PubMed Web of Science ®Google Scholar
• Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J. Urol.176(6 Pt 2), S66–S71 (2006).
   Google Scholar
• Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol.27(23), 3742–3748 (2009).
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol.26(28), 4563–4571 (2008).
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet375(9724), 1437–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Smaletz O, Scher HI. Outcome predictions for patients with metastatic prostate cancer. Semin. Urol. Oncol.20(2), 155–163 (2002).
   Google Scholar
• Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol.10(10), 981–991 (2009).
   PubMed Web of Science ®Google Scholar
• Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab.21(5), 315–324 (2010).
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer1(1), 34–45 (2001).
   PubMed Web of Science ®Google Scholar
• Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev. Endocrinol. Metab.4(5), 417–422 (2009).
   PubMedGoogle Scholar
• Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med.332(21), 1393–1398 (1995).
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P et al.In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet.9(4), 401–406 (1995).
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med.10(1), 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer120(4), 719–733 (2007).
   PubMed Web of Science ®Google Scholar
• Xu K, Shimelis H, Linn DE et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell15(4), 270–282 (2009).
   PubMedGoogle Scholar
• Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays29(12), 1227–1238 (2007).
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract. Res. Clin. Endocrinol. Metab.22(2), 243–258 (2008).
   Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res.68(13), 5469–5477 (2008).
   PubMed Web of Science ®Google Scholar
• Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res.69(6), 2305–2313 (2009).
   PubMed Web of Science ®Google Scholar
• Hu R, Dunn TA, Wei S et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res.69(1), 16–22 (2009).
   PubMed Web of Science ®Google Scholar
• Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science240(4850), 324–326 (1988).
   PubMed Web of Science ®Google Scholar
• Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science240(4850), 327–330 (1988).
   PubMed Web of Science ®Google Scholar
• Trapman J, Klaassen P, Kuiper GG et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem. Biophys. Res. Commun.153(1), 241–248 (1988).
   PubMed Web of Science ®Google Scholar
• Gelmann EP. Molecular biology of the androgen receptor. J. Clin. Oncol.20(13), 3001–3015 (2002).
   PubMed Web of Science ®Google Scholar
• Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem.266(1), 510–518 (1991).
   PubMed Web of Science ®Google Scholar
• Tanner T, Claessens F, Haelens A. The hinge region of the androgen receptor plays a role in proteasome-mediated transcriptional activation. Ann. NY Acad. Sci.1030, 587–592 (2004).
   PubMedGoogle Scholar
• Saporita AJ, Zhang Q, Navai N et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J. Biol. Chem.278(43), 41998–42005 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J. Biol. Chem.269(18), 13115–13123 (1994).
   PubMed Web of Science ®Google Scholar
• Zhou ZX, Kemppainen JA, Wilson EM. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol.9(5), 605–615 (1995).
   PubMedGoogle Scholar
• Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas63(2), 142–148 (2009).
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev.23(2), 175–200 (2002).
   PubMed Web of Science ®Google Scholar
• Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev.28(7), 778–808 (2007).
   PubMed Web of Science ®Google Scholar
• Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res.57(2), 314–319 (1997).
   PubMed Web of Science ®Google Scholar
• Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res.69(7), 2912–2918 (2009).
   PubMed Web of Science ®Google Scholar
• Leversha MA, Han J, Asgari Z et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res.15(6), 2091–2097 (2009).
   PubMed Web of Science ®Google Scholar
• Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res.61(9), 3550–3555 (2001).
   PubMed Web of Science ®Google Scholar
• Ford OH 3rd, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol.170(5), 1817–1821 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer89(3), 552–556 (2003).
   PubMed Web of Science ®Google Scholar
• Moul JW, Srivastava S, McLeod DG. Molecular implications of the antiandrogen withdrawal syndrome. Semin. Urol.13(2), 157–163 (1995).
   Google Scholar
• Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res.15(15), 4792–4798 (2009).
   PubMed Web of Science ®Google Scholar
• Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr. Opin. Oncol.22(3), 263–267 (2010).
   PubMed Web of Science ®Google Scholar
• Vasaitis T, Belosay A, Schayowitz A et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{α}-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol. Cancer Ther.7(8), 2348–2357 (2008).
   PubMed Web of Science ®Google Scholar
• Handratta VD, Vasaitis TS, Njar VC et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem.48(8), 2972–2984 (2005).
   PubMed Web of Science ®Google Scholar
• Donovan MJ, Hamann S, Clayton M et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J. Clin. Oncol.26(24), 3923–3929 (2008).
   Google Scholar
• Cordon-Cardo C, Kotsianti A, Verbel DA et al. Improved prediction of prostate cancer recurrence through systems pathology. J. Clin. Invest.117(7), 1876–1883 (2007).
   PubMed Web of Science ®Google Scholar
• Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol.164(6), 1992–1995 (2000).
   PubMed Web of Science ®Google Scholar
• Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int.95(9), 1327–1335 (2005).
   PubMed Web of Science ®Google Scholar
• Niu Y, Altuwaijri S, Lai KP et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl Acad. Sci. USA105(34), 12182–12187 (2008).
   PubMed Web of Science ®Google Scholar
• Culig Z, Stober J, Gast A et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect. Prev.20(1), 68–75 (1996).
   PubMedGoogle Scholar
• Culig Z, Hobisch A, Cronauer MV et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol.7(12), 1541–1550 (1993).
   PubMed Web of Science ®Google Scholar
• Taplin ME, Rajeshkumar B, Halabi S et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol.21(14), 2673–2678 (2003).
   PubMed Web of Science ®Google Scholar
• Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res.60(4), 944–949 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol.46(6), 759–765 (1993).
   PubMed Web of Science ®Google Scholar
• Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J. Pathol.189(4), 559–563 (1999).
   PubMed Web of Science ®Google Scholar
• Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res.59(11), 2511–2515 (1999).
   PubMed Web of Science ®Google Scholar
• Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat.23(6), 527–533 (2004).
   PubMed Web of Science ®Google Scholar
• Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin. Chem.44(4), 705–723 (1998).
   PubMed Web of Science ®Google Scholar
• Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol.195(2), 138–146 (2001).
   PubMed Web of Science ®Google Scholar
• Matias PM, Donner P, Coelho R et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem.275(34), 26164–26171 (2000).
   PubMed Web of Science ®Google Scholar
• Sack JS, Kish KF, Wang C et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl Acad. Sci. USA98(9), 4904–4909 (2001).
   PubMed Web of Science ®Google Scholar
• Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res.2(2), 277–285 (1996).
   PubMed Web of Science ®Google Scholar
• Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res.62(5), 1496–1502 (2002).
   PubMed Web of Science ®Google Scholar
• Ceraline J, Cruchant MD, Erdmann E et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int. J. Cancer108(1), 152–157 (2004).
   PubMed Web of Science ®Google Scholar
• Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol.5(10), 1396–1404 (1991).
   PubMed Web of Science ®Google Scholar
• Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res.61(11), 4315–4319 (2001).
   PubMed Web of Science ®Google Scholar
• Halkidou K, Gnanapragasam VJ, Mehta PB et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene22(16), 2466–2477 (2003).
   PubMed Web of Science ®Google Scholar
• Agoulnik IU, Vaid A, Nakka M et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res.66(21), 10594–10602 (2006).
   PubMed Web of Science ®Google Scholar
• Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol.23(4), 572–583 (2009).
   PubMedGoogle Scholar
• Gregory CW, Fei X, Ponguta LA et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem.279(8), 7119–7130 (2004).
   PubMed Web of Science ®Google Scholar
• Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem.277(41), 38087–38094 (2002).
   PubMedGoogle Scholar
• Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res.58(20), 4640–4645 (1998).
   PubMed Web of Science ®Google Scholar
• Krueckl SL, Sikes RA, Edlund NM et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res.64(23), 8620–8629 (2004).
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin. Cancer Res.11(5), 1815–1820 (2005).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Tortora G, D’Armiento FP et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res.8(11), 3438–3444 (2002).
   PubMed Web of Science ®Google Scholar
• Gioeli D, Ficarro SB, Kwiek JJ et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem.277(32), 29304–29314 (2002).
   PubMed Web of Science ®Google Scholar
• Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med.5(3), 280–285 (1999).
   PubMed Web of Science ®Google Scholar
• Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA96(10), 5458–5463 (1999).
   PubMed Web of Science ®Google Scholar
• Ittmann MM. Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol. Rep.5(6), 1329–1335 (1998).
   PubMedGoogle Scholar
• Graff JR, Konicek BW, McNulty AM et al.Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem.275(32), 24500–24505 (2000).
   PubMed Web of Science ®Google Scholar
• Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl Acad. Sci. USA98(13), 7200–7205 (2001).
   PubMed Web of Science ®Google Scholar
• Wen Y, Hu MC, Makino K et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res.60(24), 6841–6845 (2000).
   PubMed Web of Science ®Google Scholar
• Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res.63(8), 1981–1989 (2003).
   PubMed Web of Science ®Google Scholar
• McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br. J. Cancer98(6), 1094–1101 (2008).
   PubMed Web of Science ®Google Scholar
• Guo Z, Dai B, Jiang T et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell10(4), 309–319 (2006).
   PubMed Web of Science ®Google Scholar
• Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res.66(22), 11047–11054 (2006).
   PubMedGoogle Scholar
• Mahajan NP, Liu Y, Majumder S et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl Acad. Sci. USA104(20), 8438–8443 (2007).
   PubMed Web of Science ®Google Scholar
• Mahajan K, Mahajan NP. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J. Cell Physiol. (2010).
   Google Scholar
• Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res.15(10), 3540–3549 (2009).
   PubMed Web of Science ®Google Scholar
• Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin. Cancer Res.15(10), 3251–3255 (2009).
   PubMed Web of Science ®Google Scholar
• Chi KN, Bjartell A, Dearnaley D et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur. Urol.56(4), 594–605 (2009).
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res.12(6), 1665–1671 (2006).
   PubMed Web of Science ®Google Scholar
• Labrie C, Simard J, Zhao HF, Belanger A, Pelletier G, Labrie F. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology124(6), 2745–2754 (1989).
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology. Mol. Cell Endocrinol.78(3), C113–C118 (1991).
   PubMed Web of Science ®Google Scholar
• Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell. Endocrinol.295(1–2), 115–120 (2008).
   PubMed Web of Science ®Google Scholar
• Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res.68(15), 6407–6415 (2008).
   PubMed Web of Science ®Google Scholar
• Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J. Urol.132(4), 693–696 (1984).
   PubMed Web of Science ®Google Scholar
• Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res.11(13), 4653–4657 (2005).
   PubMed Web of Science ®Google Scholar
• Mohler JL, Gregory CW, Ford OH 3rd et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res.10(2), 440–448 (2004).
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J. Urol.178(4 Pt 1), 1282–1288 (2007).
   Google Scholar
• Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res.10(21), 7121–7126 (2004).
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res.66(5), 2815–2825 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68(11), 4447–4454 (2008).
   PubMed Web of Science ®Google Scholar
• Hofland J, van Weerden WM, Dits NF et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res.70(3), 1256–1264 (2010).
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol. Oncol.27(3), 251–257 (2009).
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids62(1), 133–142 (1997).
   PubMed Web of Science ®Google Scholar
• Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer100(5), 671–675 (2009).
   PubMed Web of Science ®Google Scholar
• Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Semin. Reprod. Med22(4), 281–288 (2004).
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS et al.Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol.28(9), 1496–1501 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol.8(4), 440–448 (2008).
   PubMed Web of Science ®Google Scholar
• Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med.351(15), 1488–1490 (2004).
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Berges R. From pathogenesis to prevention of castration resistant prostate cancer. Prostate70(1), 100–112 (2010).
   Google Scholar
• Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate53(2), 118–123 (2002).
   PubMed Web of Science ®Google Scholar
• Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann. Oncol.12(Suppl. 2), S141–S144 (2001).
   Google Scholar
• Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res.26(5B), 3693–3700 (2006).
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Mitsiades CS, Bogdanos J et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin. Cancer Res.10(13), 4398–4405 (2004).
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J. Clin. Endocrinol. Metab.86(12), 5729–5736 (2001).
   PubMed Web of Science ®Google Scholar
• Colombel M, Symmans F, Gil S et al. Detection of the apoptosis-suppressing oncoprotein bc1–2 in hormone-refractory human prostate cancers.Am. J. Pathol.143(2), 390–400 (1993).
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res.52(24), 6940–6944 (1992).
   PubMed Web of Science ®Google Scholar
• Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res.2(2), 389–398 (1996).
   PubMed Web of Science ®Google Scholar
• Gleave M, Tolcher A, Miyake H et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res.5(10), 2891–2898 (1999).
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Platz EA, Sutcliffe S et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer7(4), 256–269 (2007).
   PubMed Web of Science ®Google Scholar
• Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature464(7286), 302–305 (2010).
   PubMed Web of Science ®Google Scholar
• Nadiminty N, Lou W, Sun M et al. Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells. Cancer Res.70(8), 3309–3319 (2010).
   PubMedGoogle Scholar
• Khor LY, Bae K, Pollack A et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92–02 trial. Lancet Oncol.8(10), 912–920 (2007).
   PubMed Web of Science ®Google Scholar
• Di Silverio F, Sciarra A, Gentile V. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. Urology71(5), 947–951 (2008).
   Google Scholar